Evidence map›Paper›PMID 38633388›Full record

ArticleComputational and structural biotechnology journal2024

Co-expression of immune checkpoints in glioblastoma revealed by single-nucleus RNA sequencing and spatial transcriptomics.

Dingyi Yuan, Wenting Chen, Shasha Jin, Wei Li, Wanmei Liu, Liu Liu, Yinhao Wu, Yuxin Zhang, Xiaoyu He, Jingwei Jiang and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Computational and structural biotechnology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. [IGSF11: A Novel Target for Cancer Immunotherapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Dingyi YuanNew Drug Screening and Pharmacodynamics Evaluation Center, China Pharmaceutical University, Nanjing, China.
Wenting ChenNew Drug Screening and Pharmacodynamics Evaluation Center, China Pharmaceutical University, Nanjing, China.
Shasha JinNew Drug Screening and Pharmacodynamics Evaluation Center, China Pharmaceutical University, Nanjing, China.
Wei LiDepartment of Neurosurgery, the Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing, China.
Wanmei LiuNew Drug Screening and Pharmacodynamics Evaluation Center, China Pharmaceutical University, Nanjing, China.
Liu LiuJiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing, China.
Yinhao WuNew Drug Screening and Pharmacodynamics Evaluation Center, China Pharmaceutical University, Nanjing, China.
Yuxin ZhangNew Drug Screening and Pharmacodynamics Evaluation Center, China Pharmaceutical University, Nanjing, China.
Xiaoyu HeNew Drug Screening and Pharmacodynamics Evaluation Center, China Pharmaceutical University, Nanjing, China.
Jingwei JiangNew Drug Screening and Pharmacodynamics Evaluation Center, China Pharmaceutical University, Nanjing, China.
Hongbin SunJiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing, China.
Xiangyu LiuDepartment of Neurosurgery, the Affiliated Drum Tower Hospital, School of Medicine, Nanjing University, Nanjing, China.
Jun LiuNew Drug Screening and Pharmacodynamics Evaluation Center, China Pharmaceutical University, Nanjing, China.
China Pharmaceutical University · CNNanjing Drum Tower Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glioblastoma (GBM) is one of the most malignant tumors of the central nervous system. The pattern of immune checkpoint expression in GBM remains largely unknown. We performed snRNA-Seq and spatial transcriptomic (ST) analyses on untreated GBM samples. 8 major cell types were found in both tumor and adjacent normal tissues, with variations in infiltration grade. Neoplastic cells_6 was identified in malignant cells with high expression of invasion and proliferator-related genes, and analyzed its interactions with microglia, MDM cells and T cells. Significant alterations in ligand-receptor interactions were observed, particularly between Neoplastic cells_6 and microglia, and found prominent expression of VISTA/VSIG3, suggesting a potential mechanism for evading immune system attacks. High expression of TIM-3, VISTA, PSGL-1 and VSIG-3 with similar expression patterns in GBM, may have potential as therapeutic targets. The prognostic value of VISTA expression was cross-validated in 180 glioma patients, and it was observed that patients with high VISTA expression had a poorer prognosis. In addition, multimodal cross analysis integrated SnRNA-seq and ST, revealing complex intracellular communication and mapping the GBM tumor microenvironment. This study reveals novel molecular characteristics of GBM, co-expression of immune checkpoints, and potential therapeutic targets, contributing to improving the understanding and treatment of GBM.

Indexed as

Cell-cell communicationGlioblastomaImmune checkpointsSingle-nucleus RNA sequencingSpatial transcriptomics

Identifiers

PMID38633388
PMCPMC11021796
OpenAlexW4394693703

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.